Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced its underwritten public offering of 5 million shares of common stock at $20.00 per share, expected to generate gross proceeds of approximately $100 million. The offering, which includes a 30-day option for underwriters to purchase up to an additional 750,000 shares, is anticipated to close on or about July 1, 2026, subject to customary conditions. The company intends to use the net proceeds to advance development of its lead programs—NXP100, NXP200, and NXP900—support future product candidates, hire additional personnel, fund capital expenditures, and cover general corporate purposes.
This capital raise is significant for Nuvectis as it seeks to progress its pipeline of innovative therapies. NXP100 is a late-stage complement Factor B inhibitor with best-in-class potential for multiple complement-mediated diseases, offering a once-daily oral treatment option. NXP900 is an oral small molecule inhibitor targeting the SRC Family of Kinases, including SRC and YES1, designed to comprehensively shut down signaling pathways in advanced cancers. NXP200 is an oral, brain-penetrant BRAF inhibitor for BRAF V600X-mutated and Class II/III non-V600-mutated solid tumors, including central nervous system cancers, colorectal cancer, melanoma, and non-small cell lung cancer.
The offering is being led by Cantor as sole book-running manager, with co-managers including H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners. The successful closure of this offering will provide Nuvectis with substantial financial resources to accelerate its clinical programs and potentially bring new treatment options to patients with unmet medical needs. For more details, the full press release is available at https://ibn.fm/SrZnr.
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune complement-related conditions and oncology. Its pipeline addresses significant medical needs, and the proceeds from this offering will be critical in advancing these candidates through clinical development. The company's strategy emphasizes best-in-class potential, particularly for NXP100 as a convenient oral therapy for chronic complement-mediated diseases, and for NXP200 in treating challenging solid tumors with brain metastases. As Nuvectis progresses, the investment community will be watching for clinical data and regulatory milestones. More information about the company can be found at https://nuvectis.com/.
